回盛生物: 关于向特定对象发行股票的审核问询函回复及募集说明书等申请文件更新的提示性公告

Group 1 - The company received an inquiry letter from Shenzhen Stock Exchange regarding its application for a specific stock issuance on July 25, 2025 [1] - The company, along with relevant intermediaries, has carefully studied and responded to the questions raised in the inquiry letter, updating the prospectus and related application documents accordingly [1] - The financial data and other changes in the prospectus have been synchronized with the recently disclosed 2025 semi-annual report [1] Group 2 - The stock issuance is subject to approval from the Shenzhen Stock Exchange's listing review center and the China Securities Regulatory Commission [2] - There is uncertainty regarding whether the company will pass the Shenzhen Stock Exchange review and obtain registration approval from the China Securities Regulatory Commission [2] - The company will fulfill its information disclosure obligations based on the progress of this matter [2]